The tool — called the Cryosection Histopathology Assessment and Review Machine, or CHARM — studies images to quickly pick out the genetic profile of a kind of tumor called glioma, a process that currently takes days or weeks.
Category: biotech/medical – Page 540
UMass Amherst researchers have pushed forward the boundaries of biomedical engineering one hundredfold with a new method for DNA detection with unprecedented sensitivity.
“DNA detection is in the center of bioengineering,” says Jinglei Ping, lead author of the paper that appeared in Proceedings of the National Academy of Sciences.
Ping is an assistant professor of mechanical and industrial engineering, an adjunct assistant professor in biomedical engineering and affiliated with the Center for Personalized Health Monitoring of the Institute for Applied Life Sciences. “Everyone wants to detect the DNA at a low concentration with a high sensitivity. And we just developed this method to improve the sensitivity by about 100 times with no cost.”
An internationally-renowned Iranian scientist and this year’s winner of Iran’s prestigious Mustafa Prize for science and technology has hailed the country’s great advances in the fields of nanotechnology and medicine.
“Iran has always been far ahead in the field of nanotechnology,” Omid Farokhzad, who has won the prize for design, development, and clinical translation of novel polymeric nanomedicines used to treat various diseases, especially cancer, said on Monday.
Discover how THALES collaborates with the CNRS to identify new genetic markers leading to the development of pediatric cancers, thereby contributing to the improvement of patient care.
Lung cancer screening is crucial for decreasing the death count from the disease but the government can’t scan everyone’s lungs. Here is an AI that identifies people who actually need screening.
Lung cancer is the deadliest cancer type, killing over a million people annually across the globe. The disease is responsible for the highest number of cancer deaths in both men and women in the US.
In fact, the death toll from lung cancer among women and men is nearly triple that of breast cancer and prostate cancer, respectively.
Venture Investing To Catalyze The Next Generation Of Founder-Led, Longevity Biotech Companies — Dr. Alex Colville, Ph.D., Co-Founder and General Partner — age1.
Dr. Alex Colville, Ph.D. is Co-Founder and General Partner of age1 (https://age1.com/), a venture capital firm focused on catalyzing the next generation of founder-led, longevity biotech companies, with a strategy of building a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related diseases.
With a recent initial closing of US$35 million, age1 will be focusing on founders and companies at the earliest stages of first-money in, pre-seed and seed funding, and is resourced to continue to support companies through later rounds.
Professor René Ketting’s team at the Institute of Molecular Biology (IMB) in Mainz, Germany, along with Dr. Sebastian Falk’s group at the Max Perutz Labs in Vienna, Austria, have discovered a new enzyme, PUCH, which plays a key role in preventing the spread of parasitic DNA
DNA, or deoxyribonucleic acid, is a molecule composed of two long strands of nucleotides that coil around each other to form a double helix. It is the hereditary material in humans and almost all other organisms that carries genetic instructions for development, functioning, growth, and reproduction. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).
Detect Cancers Early
Posted in biotech/medical
Read about the goal to detect and treat cancers at early stages, enable effective treatments, and reduce cancer cases and deaths.
Mini-brains that work and grow like their full-size counterparts could offer an alternative to animal testing, and advance the quest for personalized medicine.
Phage viruses that target bacteria have been known for a century but there are still no clinical trials – though compassionate treatment of patients with pseudomonas shows huge success.